Member Info for sajy

I emailed the company. Anyone who has any concerns should contact Dest. I feel very relaxed now as there is nothing to worry about, just waiting on NIAID. Must be any day now considering 3 weeks have passed.

Tatty, NIAID have been doing pre clincal trials using XF-73 for burns and wounds. They have been doing this work since early 2023. Originally it was only meant to be a small trial with results announced in June 2023, however NIAID decided to expand the trial. Destiny now have results of the trial and will be announcing it any day now. The slight delay is explained in my email below.

I have been looking into the reason for the delay in announcing the NIAID results. The RNS that Dest will be releasing has to be checked and agreed by NIAID. NIAID is a notoriously slow organisation and hence the slight delay. As soon as Dest get the nod the RNS will be released.

I have been going through the end of year Rns again and noticed that they mention 'evaluating all options' TWICE in the Rns when referring to XF-73. I did ask the company if they had received an offer from someone to buy the rights to XF-73 and if so would they sell. The answer was No Comment, why not say no if they hadn't. I am now starting to think that they must be discussing licensing deals as well as either selling part of the rights for XF-73 or all the rights.

So the question is what is part or all rights to Xf-73 worth? As a shareholder I would like to see around $200M for just the post surgical infections rights and $500M for all the rights to XF-73. Would be interested to hear what valuation you guys think they are worth.

On the 20th of December 2023 #RUA said “A major heart valve company has approached the Company to undertake its own tests and has now entered into a material testing agreement (MTA) in order to do so.” This could well be the company they are working with “Edwards Lifesciences” which only a month ago announced it will spin off its critical care unit in 2024 to focus on heart devices as it’s a huge market. The market cap of $EW Edwards Lifesciences is $44 Billion and listed on the NYSE. Whilst I can’t say with any certainty this is the actual company #RUA are working with, it sure fits the description and would tie in with announcements from both companies but if this was to be announced the stock would multi bag. Some food for thought. As always please DYOR and don’t just take my word for it as this is from my own research and not factual but wouldn’t it be nice if it were to be announced. In the meantime gap fill to 20p on the chart is coming IMO.

This is what I posted on X earlier today in response to a tweet about todays update.

The bit about considering all options caught my eye. Pure speculation on my part but I have always had this feeling that one of the big boys would rather have XF-73 all to themselves than share with Dest. Could a part or all rights offer for XF-73 be the reason for delay.

I have brought the above to your attention as nick2412 has done an excellent post on ADVFN which goes into a lot more detail but is very similar to what my thoughts were after the update today. I suggest you read it.

Rebess no doubt has sold out. You make it so obvious. Nothing wrong with selling if that's how you feel, but to then come back and deramp is poor.

Rumours that Wcat PSA has been signed and sp up 70%. If true maybe ours will follow shortly, fingers crossed.

Come on then danrh I am all ears, please explain all the risks you are on about and share the wealth of knowledge you have on pharmaceuticals. By the way I have been tipping destiny when it was in the 30p range so most who followed me will be very happy now at 81p. What a prat.

For those of you who have been reading my posts will know by now how highly I rate XF-73. I have stated many times that it will be a Blockbuster drug and that it will eventually be the standard of care for virtually every operation in the future and this was confirmed by the company when I asked them in the recent presentation.

Now our CEO is also very excited about XF-73 and I will list some quotes below from him in my recent email exchange with him.

'We are totally focused on securing the best possible deal for our key stakeholders and one that makes the most of the significant market opportunity for this incredible product'.

'The incredible opportunities for XF-73 nasal in terms of both saving lives once it is approved and delivering for shareholders is the main reason I was so excited to join Destiny, and it remains my absolute priority to deliver on both these opportunities'.

I am expecting an update on XF-73 this week and what a great end to the year it would be if they confirm that they have entered exclusivity with a Global Top Ten Pharma. That would mean that I could still be correct as I stated our partner will be either GSK or Pfizer. GLA

Looks like everyone is loading up before the update next week.

It's only a matter of time before Dest get's taken over, but I don't want that to happen just yet. Maybe in about 12 to 18 months time we get taken over for about a billion.

Noix that is correct, but what most people don't know is that the initial study was done in Q1 2023 by NIAID and then they decided to expand the work. You have to ask yourself, why would NIAID do that? My understanding is the results were very good and that is the reason for further work. I am expecting an excellent update on the NIAID trials.

I am pretty confident we will get an update on or before the 22nd December, that's only 10 trading days to go. Hopefully a similar share price reaction to what we had in December last year when the company provided an update on M3. The share price rose by about 50%.

I have bought in recently and would appreciate others thoughts on what I think Altn will be producing next year.

I have them producing 50K ounces of gold. If aisc are $1100 and say gold price at $2000, then they should be generating $45Million profit before tax. They should be able to pay the debt of pretty quick and then start paying dividends.

I had a long chat with IR yesterday and it's too long to post everything so will mention what I think were the important points.

Company are still on track to publish AD for South Sudan on or before 15th December. I asked if the company could extend the deadline if work streams not completed and stay suspended. Response was we have not sought advice on that. This was very interesting for me as I asked the same question in September and the answer was we have sought advice and been told we can extend deadline and stay suspended. So the questions arises why have they not sought advice this time.

I asked what the work streams are and was told it is gaining approval from various different departments and then Government approval. AK has been and is still in SS and that is what he has been doing.

Accugas debt refinance is still expected to complete before end of 2023 and will issue an Rns.

Re Chad, some major changes would have to take place for Save to start discussions with the Chad Government and preferred route is still via ICC.

No plans to issue a trading update before the end of 2023.

Not much happening in Niger, it is a wait and see situation for now.

As we all know Dest were in discussions with multiple global pharma and this has been confirmed by CT. I believe that the company are now in exclusive discussions with a global pharma and the upfront payment, milestones and royalties are being discussed. I am pretty convinced that we will get an update soon.

Pro this is chat board and I am free to post what I hear, nobody is asking you to believe it and even I take it with a pinch of salt as after all they are rumours. I suggest you stop behaving like the chat board police and stop making accusations.

I posted on here a few months ago that I had heard that both GSK and Pfizer had shown an interest. I cannot confirm this as they are rumours but my money is on GSK. Look at the evidence, GSK are into AMR in a big way and many of our directors used to work for GSK. I have always maintained XF-73 will be a blockbuster drug and all the evidence points to that, so why would GSK not be interested. Not long now before we get an update.

DT, I am expecting the following updates in December.

1. Update on NIAID trial results.

2. Update on XF-73 licensing deal.

In my discussions with Destiny, I have been told this is a very busy period for the company.